<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006680</url>
  </required_header>
  <id_info>
    <org_study_id>1303M29681</org_study_id>
    <nct_id>NCT02006680</nct_id>
  </id_info>
  <brief_title>Markers of Pubertal Suppression During Therapy for Precocious Puberty</brief_title>
  <official_title>Markers of Adequate Pubertal Suppression During Supprelin LA Therapy for Central Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atlantic Center for Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Goryeb Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The best way to measure whether treatment of children with central precocious puberty is&#xD;
      working is to do a hormone stimulation test (leuprolide stimulation test) that requires&#xD;
      injection of a medication and multiple blood draws to see if the hormonal response is&#xD;
      suppressed (blocked). The hypothesis of this study is that random measurement of the free&#xD;
      alpha subunit of pituitary glycoprotein, a protein related to the pituitary hormones that&#xD;
      stimulate puberty, will provide an adequate alternative to the leuprolide stimulation testfor&#xD;
      monitoring efficacy of pubertal suppression with Supprelin LA速.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During clinical trials of Supprelin LA速, leuprolide stimulation tests were performed to&#xD;
      determine adequacy of suppression. However, the use of this stimulation test to monitor&#xD;
      suppression requires an expensive medication and collection of multiple blood samples.&#xD;
      Alternative methods of monitoring pubertal suppression during gonadotropin releasing hormone&#xD;
      receptor agonist (GnRHa) therapy have included both random and trough levels of Luteinizing&#xD;
      Hormone (LH), estradiol or inhibin B. Recently, the free alpha subunit of pituitary&#xD;
      glycoprotein (FASPG) has also been shown to be a potentially useful marker of hormonal&#xD;
      suppression (Hirsch HJ, et al, JCEM 95:2841, 2010) as it undergoes a paradoxical rise&#xD;
      following initiation of therapy, and reverts to baseline upon completion.&#xD;
&#xD;
      In this investigator-initiated pilot study we will evaluate novel markers of pubertal&#xD;
      suppression in children receiving standard of care gonadotropin releasing hormone receptor&#xD;
      agonist therapy for the treatment of central precocious puberty. Children with central&#xD;
      precocious puberty who have selected treatment with Supprelin LA will undergo hormonal&#xD;
      testing of markers of pubertal activity before and after placement of the Supprelin LA&#xD;
      insert.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate Recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of free alpha subunit of pituitary glycoprotein to identify subjects with appropriate pubertal suppression.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The primary outcome of the study will be the sensitivity and specificity of a subject having elevated random FASPG values (&gt; 0.6 ng/mL) to identify subjects who are appropriately suppressed based upon a leuprolide-stimulated LH &lt;4 mIU/mL. This outcome will be based upon results of puberty hormone suppression testing obtained 28-97 days after placement of the Supprelin LA insert.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4</enrollment>
  <condition>Central Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Children with Central Precocious Puberty</arm_group_label>
    <description>Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum will be collected at four different time points.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Females diagnosed with central precocious puberty or rapidly progressive puberty based upon&#xD;
        age at start of puberty, physical examination, serum hormone levels and bone age X-Ray will&#xD;
        be recruited. This will be a convenience sample of children scheduled to receive Supprelin&#xD;
        LA insert placement. The subjects will be recruited from two pediatric endocrinology clinic&#xD;
        systems.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age: 3 to 9 years old, inclusive&#xD;
&#xD;
          -  Diagnosis of Central Precocious or Rapidly Progressive Puberty&#xD;
&#xD;
          -  Bone Age more than 1 year advanced (obtained within 6 months of screening) AND&#xD;
&#xD;
          -  Breasts Tanner II or greater AND&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
          -  Random LH &gt; 1 mIU/mL&#xD;
&#xD;
          -  Leuprolide-stimulated LH &gt; 4 mIU/mL&#xD;
&#xD;
          -  Random estradiol &gt; 20 pg/mL&#xD;
&#xD;
          -  Leuprolide-stimulated 24 hour estradiol &gt;20 pg/mL&#xD;
&#xD;
          -  Na誰ve to GnRHa therapy&#xD;
&#xD;
          -  Approved to receive Supprelin LA速 therapy&#xD;
&#xD;
          -  Have an acceptable surrogate capable of giving consent on the subject's behalf.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous GnRHa therapy&#xD;
&#xD;
          -  Presence of peripheral precocious puberty including CAH&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley S Miller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Center for Research</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.atlantichealth.org/goryeb/our+services/pediatric+diabetes+and+endocrinology/</url>
    <description>Pedatric Diabetes and Endocrinology at Goryeb Children's Hospital</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Precocious Puberty</keyword>
  <keyword>Suppression</keyword>
  <keyword>Alpha Subunit</keyword>
  <keyword>Leuprolide Stimulation Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

